A CALL TO ACTION TO ADDRESS RACIAL INEQUITIES IN MEDICAL TESTS

Clinical algorithms that adjust for race can lead to disparities in care.

Washington, DC (March 5, 2021) — A new perspective article published in CJASN examines how the use of race in calculating kidney function, as well as other aspects of health, can cause harm to patients.

The authors—Richard E. Neal, the Chairman of the Committee on Ways and Means in the House of Representatives, and Michelle Morse, MD, MPH, an internal medicine and public health doctor who works on global health equity, social medicine, and racial justice, and was recently named the first-ever Chief Medical Officer of New York City’s Department of Health and Mental Hygiene—explain that currently a modifier for Black race in calculations of kidney health indicates that the Black patient has higher kidney function. This could delay access to additional tests and treatments. Other examples of misuse of race in clinical algorithms exist across diverse areas of medicine.

Numerous institutions have decided to end reporting of the race modifier used in kidney care because of these concerns. Also, in response to letters sent by the Committee on Ways and Means, professional medical societies have agreed that the use and misuse of race and ethnicity in clinical algorithms needs to be re-evaluated with more research on the unintended consequences of removing race correctors. The authors argue that “this circular lack of accountability cannot continue.”

Neal and Morse stress that the medical community must step up to achieve consensus on paths forward. “Data on race and ethnicity should be rigorously and consistently collected and used to measure the social and health impact of racism, not for biological racial distinctions,” they wrote. “To this day, racial differences in outcomes are often misinterpreted as biological differences instead of the result of social and structural forces.”

The perspective is part of a Disparities and Workforce Diversity collection developed by CJASN.

Of note, the Agency for Healthcare Research and Quality, which is part of the U.S. Department of Health & Human Services, is requesting information and evidence on
clinical algorithms that may introduce bias into clinical decision making and/or influence access to care, quality of care, or health outcomes for racial and ethnic minorities and people who are socioeconomically disadvantaged.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.